P Lichter
Overview
Explore the profile of P Lichter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
242
Citations
7061
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pixberg C, Zapatka M, Hlevnjak M, Benedetto S, Suppelna J, Heil J, et al.
ESMO Open
. 2022 Nov;
7(6):100637.
PMID: 36423362
Background: COGNITION (Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials) is a diagnostic registry trial...
2.
Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova M, et al.
Neuropathol Appl Neurobiol
. 2018 Oct;
45(2):108-118.
PMID: 30326163
Aims: Mutations of isocitrate dehydrogenase (IDH)1/2 affect almost all astrocytomas of WHO grade II and III. A subset of IDH-mutant astrocytic tumours progresses to IDH-mutant glioblastoma or presents with the...
3.
Kawauchi D, Ogg R, Liu L, Shih D, Finkelstein D, Murphy B, et al.
Oncogene
. 2017 May;
36(37):5231-5242.
PMID: 28504719
Group3 medulloblastoma (MB) that predominantly occur in young children are usually associated with MYC amplification and/or overexpression, frequent metastasis and a dismal prognosis. Physiologically relevant MB models are currently lacking,...
4.
Thewes V, Simon R, Hlevnjak M, Schlotter M, Schroeter P, Schmidt K, et al.
Oncogene
. 2017 Mar;
36(29):4124-4134.
PMID: 28319069
Antiestrogen-resistant and triple-negative breast tumors pose a serious clinical challenge because of limited treatment options. We assessed global gene expression changes in antiestrogen-sensitive compared with antiestrogen-resistant (two tamoxifen resistant and...
5.
Ratnaparkhe M, Hlevnjak M, Kolb T, Jauch A, Maass K, Devens F, et al.
Leukemia
. 2017 Feb;
31(10):2048-2056.
PMID: 28196983
Recent developments in sequencing technologies led to the discovery of a novel form of genomic instability, termed chromothripsis. This catastrophic genomic event, involved in tumorigenesis, is characterized by tens to...
6.
Hanna B, McClanahan F, Yazdanparast H, Zaborsky N, Kalter V, Rossner P, et al.
Leukemia
. 2015 Nov;
30(3):570-9.
PMID: 26522085
Chronic lymphocytic leukemia (CLL) is characterized by apoptosis resistance and a dysfunctional immune system. Previous reports suggested a potential role of myeloid cells in mediating these defects. However, the composition...
7.
Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, et al.
Cell Death Differ
. 2014 May;
21(9):1419-31.
PMID: 24832469
p53 loss of heterozygosity (p53LOH) is frequently observed in Li-Fraumeni syndrome (LFS) patients who carry a mutant (Mut) p53 germ-line mutation. Here, we focused on elucidating the link between p53LOH...
8.
Mack S, Witt H, Piro R, Gu L, Zuyderduyn S, Stutz A, et al.
Nature
. 2014 Feb;
506(7489):445-50.
PMID: 24553142
Ependymomas are common childhood brain tumours that occur throughout the nervous system, but are most common in the paediatric hindbrain. Current standard therapy comprises surgery and radiation, but not cytotoxic...
9.
Bageritz J, Puccio L, Piro R, Hovestadt V, Phillips E, Pankert T, et al.
Cell Death Differ
. 2014 Feb;
21(6):929-40.
PMID: 24531536
Glioblastomas are highly aggressive brain tumours and are characterised by substantial cellular heterogeneity within a single tumour. A sub-population of glioblastoma stem-like cells (GSCs) that shares properties with neural precursor...
10.
Knudsen P, Hanna B, Ohl S, Sellner L, Zenz T, Dohner H, et al.
Leukemia
. 2013 Nov;
28(6):1289-98.
PMID: 24280868
Chronic lymphocytic leukemia (CLL) is an incurable malignancy of mature B cells. One of the major challenges in treatment of CLL is the achievement of a complete remission to prevent...